Table 3.
Author | Pts | Tumor | Tx intent | RTdose | CHT | MSD (Gy) | CBC | Predictors |
---|---|---|---|---|---|---|---|---|
Trip et al. (2015)15 | 90 | Gastric | A | 45 Gy (25 fx) |
Cape CDDP |
40 | - | V44 for SV decrease |
Chadha et al. (2016)23 | 177 | Pancr. | C | 50.4 Gy (25-28 fx) |
5FU Gem Cape |
6.8 | ↓ALC | V15>20% (lymphopenia SDV threshold) |
Liu et al. (2017)24 | 59 | HCC | C | 50-60 Gy (25-30 fx) |
- | 2.27 | ↓ALC | V5 and MSD for ALC |
Chin et al. (2018)26 | 21 | Esoph. | Na/C | 50 Gy (25 fx-SIB) |
CBDA- PTX 5FU/Cape |
23.4 | HT > gr.3 | V5-V20 and MSD for HT > gr.3 |
Saito et al. (2018)25 | 61 | Esoph. | C | 60 Gy (30-33 fx) |
5FU CDDP TXT |
2.87 | ↓ALC | V5-V30 and MSD for ALC (–2.9% ALC for each Gy of MSD) |
Abbreviations: 5FU = 5 flurouracil; ALC = absolute lymphocyte count; Cape = capecitabine; CBC = complete blood count; CBDA = carboplatin; CDDP = cisplatin; CHT = chemotherapy; Esoph. = esophagus; fx = fractions; Gem = gemcitabine; HCC = hepatocellular carcinoma; HT = hematological toxicity; MSD = mean spleen dose; Pancr. = pancreatic; PTX = paclitaxel; RT = radiation therapy; SDV = splenic dose volume; SIB = simultaneous integrated boost; SV = spleen volume; Tx = treatment; TXT = docetaxel.